Full-Time
Dialysis treatment solutions and training programs
$110k - $175k/yr
Junior, Mid
Indiana, USA + 1 more
More locations: Michigan, USA
Upload your resume to see how it matches 5 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Outset Medical focuses on improving dialysis treatment in the healthcare sector. Their main product, Tablo, is a system that simplifies the dialysis process by integrating with electronic medical record (EMR) platforms, allowing for better management of patient data with real-time updates and alerts. In addition to Tablo, Outset Medical provides educational modules and hands-on training for dialysis professionals, ensuring they are well-equipped to deliver care. They also offer a Vascular Access Program to enhance staff skills in cannulation and a Bridge Program to assist facilities transitioning to in-house dialysis services by providing experienced nurses for training and support. Unlike competitors, Outset Medical emphasizes a comprehensive approach to dialysis care, catering to hospitals, outpatient clinics, and home care settings. Their goal is to enhance the quality of care for dialysis patients through effective training and streamlined processes.
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Jose, California
Founded
2010
Help us improve and share your feedback! Did you find this helpful?
Medical, dental, & vision
Life Insurance/AD&D
FSA & HSA
401k
Parental leave
Pet insurance
Tuition reimbursement
PTO
Company events
Outset Medical to present at the 45th annual TD Cowen Health Care conference.
In addition to the private placement, Outset secured a $100 million term loan from Perceptive Advisors, with an option for $25 million more.
Outset Medical announced a $169 million private placement financing, issuing 843,908 shares of Series A Non-Voting Convertible Preferred Stock at $200 per share. The company also secured up to $125 million in debt financing maturing in 2030, with plans to retire $200 million in prior debt. The financing was led by PFM Health Sciences and Perceptive Advisors. Outset reported unaudited Q4 revenue of $29 million and 2024 revenue of $113 million. The transactions are expected to close by January 8, 2025.
Berman Tabacco announces that it has filed a new class action complaint against Outset Medical, Inc. with an Expanded Class Period.
To achieve this milestone, Outset partnered with Corsec, completing the validation at a Level 1 as seen in certificate #4812.